Business Context and Reporting Period
This Form 8-K was filed by Aileron Therapeutics, Inc. (trading symbol: ALRN) on June 15, 2022. The report covers corporate governance events, specifically the appointment of an interim Chief Financial Officer and the results of the Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate actions and governance updates.
Material Changes and Corporate Actions
Executive Appointment
The Board of Directors appointed Susan L. Drexler as Interim Chief Financial Officer, effective June 16, 2022. Ms. Drexler will serve as the principal financial and accounting officer under a consulting agreement with Danforth Advisors, LLC. The agreement includes an hourly rate for services and expense reimbursement, with termination provisions requiring 30 days' notice for cause and 60 days' notice without cause.
Stockholder Vote Results
At the Annual Meeting on June 15, 2022, stockholders voted on the following matters:
- Director Elections: William T. McKee and Nolan H. Sigal were elected as Class II directors for a three-year term.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-25. The Board retains discretion to set the exact ratio prior to December 31, 2022.
- Authorized Share Adjustment: Stockholders approved an amendment to adjust the number of authorized common shares based on the reverse stock split ratio.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or specific risk factors beyond the standard disclosure of the reverse stock split authorization. The appointment of an interim CFO suggests a transition in financial leadership, though no specific operational risks were detailed in this report.
Investor Verification Checklist
- Verify the exact reverse stock split ratio once determined by the Board (must be between 1-for-5 and 1-for-25).
- Monitor the transition of financial leadership under the new interim CFO, Susan L. Drexler.
- Review the impact of the reverse stock split on share price and liquidity.
- Confirm the final number of authorized shares following the implementation of the stock split.